From rapalogs to anti-aging formula

Oncotarget. 2017 May 30;8(22):35492-35507. doi: 10.18632/oncotarget.18033.

Abstract

Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor. Rational combinations of these drugs with physical exercise and an anti-aging diet (Koschei formula) can maximize their anti-aging effects and decrease side effects.

Keywords: diseases; health; lifespan; longevity; rejuvenation.

Publication types

  • Review

MeSH terms

  • Aging / drug effects*
  • Aging / physiology
  • Animals
  • Cellular Senescence / drug effects
  • Disease Susceptibility
  • Drug Discovery
  • Humans
  • Sirolimus / analogs & derivatives
  • Sirolimus / chemistry
  • Sirolimus / pharmacology*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • TOR Serine-Threonine Kinases
  • Sirolimus